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Abstract
Introduction: Antipsychotic polypharmacy (APP) and high dose (APHD) remain a common practice in the treatment 
of severe mental illness, even though they are not supported by current international guidelines.
Methods: We aimed to establish the prescribing patterns of antipsychotics in a community mental health service in a 
rural setting, to determine the prevalence of APP and APHD treatment and to identify associated factors.
Results: We identified 284 patients. APP was present in 46.5% patients and was associated to younger age, single 
status, more previous psychiatric admissions, and anticholinergic prescription. Prescription of APHD was observed in 
14.4% patients and was associated with previous inpatient admissions, being prescribed with a first generation long‑
‑acting injectable antipsychotic and anticholinergics. We also found that APP and APHD were mutually associated. 
Conclusion: Despite current guidelines, we found prevalences of APP and APHD of 46.5% and 14.4%, respectively. 
Further studies are necessary to better evaluate the antipsychotic prescription patterns in Portugal. 
Resumo
Introdução: A polifarmácia e a sobredosagem antipsicóticas permanecem uma prática comum no tratamento de 
doenças mentais graves, embora as normas mais atuais não o recomendem.
Métodos: Procurou ‑se identificar os padrões de prescrição antipsicótica num serviço comunitário com enquadramento 
rural, de forma a determinar a prevalência de polifarmácia e sobredosagem antipsicótica e fatores associados.
Resultados: Foram identificados 284 doentes. A polifármacia antipsicótica foi observada em 46,5% dos doentes e 
associava ‑se a idades mais jovens, ser solteiro, internamentos psiquiátricos prévios e prescrição de anticolinérgicos. 
Por outro lado, a sobredosagem antipsicótica foi encontrada em 14,4% dos doentes e associava ‑se a internamentos 
psiquiátricos prévios, estar medicado com um antipsicótico injetável de primeira geração de longa duração de ação e 
com um anticolinérgico. Observou ‑se também que a sobredosagem e a polifármacia estavam associadas. 
Conclusão: Apesar das recomendações internacionais, identificaram ‑se prevalências de polifarmácia e sobredosagem 
antipsicótica de 46,5% e 14,4%, respetivamente. São necessários mais estudos para melhor caracterizar os padrões de 
prescrição antipsicótica em Portugal.
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Antipsychotics are an essential component of the pharma‑
cologic arsenal of psychiatric treatment. Whilst designed 
for the treatment of psychotic disorders, their usage has 
expanded to functions such as impulse control, mood 
stabilization, sleep induction or potentiation of antidepres‑
sants.1,2 Long ‑acting injectable antipsychotic (LAIA) for‑
mulations are often used to ensure treatment adherence.3
Current guidelines recommend antipsychotic monotherapy as 
the standard care, considering polypharmacy (APP) solely as a 
last resort for refractory symptoms after multiple antipsychotic 
trials, including clozapine.4,5 Polypharmacy is defined as the 
concurrent use of two or more antipsychotics at a given time.6,7 
Guidelines also discourage antipsychotic high ‑dose (APHD) 
prescribing, defined as a total daily dose of antipsychotic 
that exceeds the maximum recommended dose, whereas in 
monotherapy or in combination with other antipsychotics.8 
Both practices are associated with several disadvantages, 
namely adverse effects, medication non ‑adherence and in‑
creased treatment7,9,10 costs though they remain common in 
clinical practice worldwide.11 ‑13 However, data regarding these 
practices in psychiatric community services is scarce. To the 
best of our knowledge, no prior studies have focused on the 
prevalence of APP and APHD in patients under the care of 
community mental health services in Portugal. 
We aimed to characterize the antipsychotic prescriptions 
patterns of a Portuguese community mental health service 
(CMHS), determine the prevalence of APP and APHD pre‑
scribing and identify associated factors. 
MATERIAL AND METHODS
a. Context
Data was collected from patients in a countryside CMHS, 
designed for individuals with serious mental illness requiring 
LAIA. Patients are referred to the CMHS by their assistant 
psychiatrist either from outpatient setting or directly from 
the inpatient service, upon patient agreement. The CMHS 
provides home visits for administration of LAIA by qualified 
nurses and regular monitorization by a psychiatrist and a so‑
cial worker. The procedure enables proximity to the patient 
with serious mental illness and promotes treatment adherence. 
b. Study design and sample
This was a retrospective and observational analysis of de‑
mographic and clinical data of patients receiving treatment 
in the CMHS in 2017. We included all patients receiving 
care for at least two months, accounting for at least one 
LAIA administration. We obtained a sample of 284 pa‑
tients. Deidentified information was extracted from clin‑
ical files and treatment management plans. Data included 
basic demographic and clinical details (gender, age, mari‑
tal status, psychiatric admissions, psychiatric diagnosis) as 
well as details on prescribed medication (oral AP, LAIA, 
anticholinergic prescription, AP total daily dose). Diagno‑
ses were classified using the 10th edition of the Internation‑
al Statistical Classification of Diseases (ICD ‑10).14
For the purpose of analysis, chlorpromazine, flupenthixol, 
fluphenazine, haloperidol and zuclopenthixol were consid‑
ered first generations antipsychotics (FGA), whereas the 
second ‑generation antipsychotics (SGA) included amisul‑
pride, aripiprazole, clozapine, olanzapine, paliperidone, 
quetiapine and risperidone.
Antipsychotic polypharmacy was defined as the concom‑
itant prescription of two or more antipsychotics. Cases 
where the same drug was prescribed in LAIA and oral 
formulations were considered as monotherapy. 
Antipsychotic HD prescription was established when the sin‑
gle or combined daily dose of antipsychotic exceed the 100% 
of maximum dose recommended in international guidelines. 
In cases of polypharmacy, the dose for each antipsychotic 
was converted to a percentage of the maximum dose, which 
were then summed to obtain the combined daily dose.15 
The study was approved by the Ethics Committee of the 
Local Mental Health Centre and the data was anonymized. 
c. Statistical methods
IBM® SPSS®, version 25, was used to analyse the data 
obtained from this study.
The data were first tested to ensure they conformed to a 
normal distribution by using the Kolmogorov ‑Smirnov 
test or by considering the values of skewness and kurto‑
sis (acceptable values for normality between  ‑2 and +2). 
Descriptive statistics included the arithmetic mean (x ̅), 
standard deviation (SD), and standard error of the mean 
(SE), as well as the 95% confidence interval (95% CI). 
Where the data were not normally distributed, the median 
and the inter ‑quartile range (IQR) were noted.
In those situations where the data were normally distribut‑
ed and the variances were constant, bivariate comparative 
analysis was made using the unpaired two ‑tailed Student’s 
t test and bivariate association analysis involved the Point 
Biserial Correlation Coefficient Test (rpb). Where the re‑
quirements for parametric statistical analysis were not 
met, bivariate comparative analysis was made using the 
Mann ‑Whitney (U) test and bivariate association analysis 
involved the Pearson Chi ‑Square (χ2) test.
The minimum level of significance (a level) accepted through‑
out the development studies was 0.05 (*), considered to be 
moderately significant. Levels of 0.01 (**) were considered 
as significant and 0.001 (***) designated as highly significant.
RESULTS
The study included 284 patients from a community mental 
health service, receiving LAIA, of whom 69% were male. 
The average age of patients in the sample was 52.73 ± 
14.36. The most prevalent marital status was single (62%). 
The most frequent diagnosis, according to the ICD ‑10, was 
schizophrenia and other psychoses (56%), with most patients 
having a history of previous psychiatric hospitalizations 
(75%). Regarding antipsychotic treatment, 53.5% were on 
monotherapy (LAIA), more frequently with FGA (76.8%), 
with haloperidol being the most prescribed (50.4%) AP. A 
total of 46.5% of the patients were in APP (oral + LAIA), 
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with the most frequent association being the combination 
FGA + SGA (60.6%). A total of 51.4% of patients were 
medicated with anticholinergics, more frequently in patients 
in APP (35.6%) than in monotherapy patients (15.8%).
A percentage of 14.4% of patients were identified as APHD 
and belong to antipsychotic polypharmacy, with no case of 
APHD being identified in antipsychotic monotherapy.
Table 1. Sociodemographic and clinical characterization of the sample
Parameter N (%)
Sex
 ‑ Male: 196 (69%);
 ‑ Female: 88 (31%)
Age  ‑ Average ± Standard deviation: 52.73 ± 14.355
Marital Status
 ‑ Single: 176 (62%);
 ‑ Married/Civil Union: 45 (15.8%);
 ‑ Divorced: 16 (5.6%);
 ‑ Widowed: 2 (6.1%);
 ‑ Not Specified: 41 (14.4%)
Previous Hospitalization
 ‑ Yes: 213 (75%);
 ‑ No: 71 (25%)
Clinical Diagnosis (ICD ‑10)
 ‑ Schizophrenia and other psychoses: 159 (56%);
 ‑ Bipolar affective disorder: 44 (15.5%);
 ‑ Depressive disorder: 4 (1.4%);
 ‑ Dementia: 4 (1.4%);
 ‑ Mental or behavioral disorders secondary to the use of psychoactive substances: 4 (1.4%);
 ‑ Others: 69 (24.3%)
AP Therapy
 ‑ AP monotherapy: 152 (53.5%)
 ‑ Oral: 0 (0%)
 ‑ LAIA: 152 (100.0%)
 ‑ FGA: 116 (76.3%)
 ‑ SGA: 36 (23.7%)
 ‑ AP polypharmacy: 132 (46.5%)
 ‑ Oral: 132 (100%)
 ‑ LAIA: 132 (100%)
 ‑ FGA: 102 (77.3%)
 ‑ SGA: 30 (22.7%)
 ‑ Associations:
 ‑ FGA+SGA: 80 (60.6%)
 ‑ SGA+SGA: 21 (15.9%)
 ‑ FGA+FGA: 21 (15.9%)
 ‑ Clozapine + FGA/SGA: 10 (7.6%)
APHD
 ‑ AP monotherapy: 0 (0%)
 ‑ AP polypharmacy:
 ‑ Oral: 41 (100%)
 ‑ LAIA: 41 (100%)
 ‑ FGA: 26 (63.4%)
 ‑ SGA: 15 (36.6%)
 ‑ Associations:
 ‑ FGA+SGA: 25 (61%)
 ‑ SGA+SGA: 10 (24.4%)
 ‑ FGA+FGA: 2 (4.9%)




 ‑ in AP monotherapy: 24 of 152 (15.8%)
 ‑ in AP polypharmacy: 47 of 132 (35.6%)
 ‑ in APHD: 16 of 41 (39%)
a. Antipsychotic polypharmacy (APP)
As already depicted, 46.5% of the patients were in APP. APP 
has shown a significant statistical association with age (p = 
0.020) and an extremely significant statistical association 
with previous hospitalization (p = 0.006) and prescription 
of anticholinergics (p = 0.000). APP showed an inverse pro‑
portional relationship with age (rpb =  ‑ 0.138), meaning that 
younger patients were more likely to be associated with APP 
than older patients. Patients with APP had a higher percent‑
age of previous hospitalizations (82.6%) when compared 
with AP monotherapy (68.4%). APP was also associated with 
a higher percentage of anticholinergic prescription (35.6%) 
when compared to AP monotherapy (15.8%).
A significant statistical difference was found between AP 
monotherapy and APP with regard to marital status (p = 
0.001) and clinical diagnosis (ICD ‑10) (p = 0.023). APP is 
predominant in single status (72.0%), whereas AP mono‑
therapy is more common in single (53.3%), married/civil 
union (19.7%) and not specified status (19.1%). Regarding 
clinical diagnosis (ICD ‑10), APP is primarily concentrated 
in schizophrenia and other psychoses (62.9%), whereas 
AP monotherapy is distributed in a wider range of psy‑
chiatric disturbances such as schizophrenia and other 
psychoses (50.0%), bipolar affective disorder (15.8%) and 
non ‑specified disturbances (28.3%).
Table 2. Antipsychotic Polypharmacy (APP) and related factors
Pair of Variables Inferential Test p ‑value
APP vs Sex
Pearson Chi ‑Square (χ2) Test
(Association Test)
0.455 (No significant statistical association)
APP vs Age
Point Biserial Correlation Coefficient Test (rpb)
(Association Test)
0.020 (Significant statistical association)
APP vs Marital Status
Mann ‑Whitney (U) Test
(Differences Test)
0.001 (Extremely significant statistical 
difference)
APP vs Previous Hospitalization
Pearson Chi ‑Square (χ2) Test
(Association Test)
0.006 (Extremely significant statistical 
association)
APP vs Clinical Diagnosis (ICD ‑10)
Mann ‑Whitney (U) Test
(Differences Test)
0.023 (Significant statistical difference)
APP vs LAIA generation type
Pearson Chi ‑Square (χ2) Test
(Association Test)
0.849 (No significant statistical association)
APP vs Anticholinergic
Pearson Chi ‑Square (χ2) Test
(Association Test)
0.000 (Extremely significant statistical 
association)
The most frequent APP combination was the FGA + SGA 
combination (60.6%), with the most frequent LAIA APP 
being haloperidol/ fluphenazine decanoate (%). Regard‑
ing oral APs, the most commonly used were olanzapine 
(23.1%) and quetiapine (20.8%). Clozapine was used in 9 
patients (6.8%).
b. Antipsychotic high doses (APHD)
As previously presented in Table 1, 14.4% of the patients 
had APHD. APHD has shown a significant statistical as‑
sociation with previous hospitalization (p = 0.015), LAIA 
generation type (p = 0.029) and prescription of anticholin‑
ergics (p = 0.025).
Patients with APHD had a higher percentage of previous 
hospitalizations (90.2%) when compared with recommend‑
ed doses of APs (72.4%). APHD had a higher percentage 
of SGA (39.0%) than recommended doses of APs (21.0%). 
APHD was also associated with a higher percentage of an‑
ticholinergic prescription (39.0%).
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Table 3. Antipsychotic High Doses (APHD) and related factors.
Pair of Variables Inferential Test p ‑value
APHD vs Sex
Pearson Chi ‑Square (χ2) Test
(Association Test)
0.534 (No significant statistical association)
APHD vs Age
Point Biserial Correlation Coefficient Test (rpb)
(Association Test)
0.386 (No significant statistical association)
APHD vs Marital Status
Mann ‑Whitney (U) Test
(Differences Test)
0.733 (No significant statistical difference)
APHD vs Previous Hospitalization Pearson Chi ‑Square (χ
2) Test 
(Association Test) 0.015 (Significant statistical association)
APHD vs Clinical Diagnosis (ICD‑
‑10)
Mann ‑Whitney (U) Test
(Differences Test)
0.057 (No significant statistical difference)
APHD vs LAIA generation type Pearson Chi ‑Square (χ
2) Test 
(Association Test) 0.029 (Significant statistical association)
APHD vs Anticholinergic Pearson Chi ‑Square (χ
2) Test 
(Association Test) 0.025 (Significant statistical association)
All 41 patients with APHD had simultaneously APP and no 
case of AP monotherapy has been registered with APHD. 
Thus, it is no surprise that an extremely significant statis‑
tical association between APP and APHD has been found 
(Pearson Chi ‑Square (χ2) Test, p = 0.000), with that asso‑
ciation being of positive nature: higher levels of APP lead 
to higher prevalence of APHD. The most frequent LAIA 
administrated in APHD is haloperidol decanoate (48.8%), 
accounting for almost half of the high dosage cases.
DISCUSSION
This study casts a light into the prescription patterns of 
antipsychotic agents in a Portuguese sample from a mental 
health community service in a rural setting. To the best of 
our knowledge, this is the first published study analysing 
APP and APHD on Portuguese patients in community men‑
tal health services. 
APP was determined to be 46.5% in the study sample. The 
scarcity of studies in this population did not allow for a 
more straightforward comparison. However, APP studies 
on other populations found much lower rates. A nation‑
‑wide study on Denmark’s schizophrenia patients found 
that the highest rate of APP dated back to 1996 (30.8%), 
showing a decrease in the following years.16 In 2012, their 
APP rate was 24.6%.16 Cotes et al17 found an APP rate of 
19% on Medicaid recipients prescribed with AP. In addi‑
tion, a meta ‑analysis12 found a global median of 19.5% of 
patients on APP. Galego et al12 also analysed APP rates 
throughout the decades, and our rate is most similar to the 
medium APP rates of Asia, North America and Europe of 
the 80’s and 90’s. 
Comparing to other Portuguese samples, we observed 
a similar APP rate in a study of AP prescription patterns 
in acute psychiatric wards (41.6%).8 On the other hand, 
Martinho et al18 studied the prevalence of APP on com‑
pulsorily admitted patients and found that 70.1% were 
discharged with an APP prescription. 
We verified that olanzapine and quetiapine were the most 
prescribed antipsychotics in the patients on APP of our 
sample. Both drugs may have been used not for their antip‑
sychotic properties, but for their action as sleep inductors. 
We did not collect data on dosage, which would have been 
helpful to discern the therapeutic rationale for the prescrip‑
tion of quetiapine and olanzapine in these patients. 
APP showed a significant statistical association with age, 
previous psychiatric admissions, and prescription of an‑
ticholinergics. On the other hand, a significant statistical 
difference between different marital status and different 
clinical diagnosis (ICD ‑10) with regard to APP prevalence 
was identified. No significant statistical association was 
found between APP and sex.
Our findings were congruent with the literature.8,16,20 ‑23 We 
did not observe an association between FGA LAIA and 
APP, contrary to a study on individuals receiving compul‑
sory treatment in the community.24 
Multiple reasons may be responsible for the high rate of APP 
in our study. In Portugal, there is a paucity of hospital beds 
in acute psychiatric wards,25 which may pressure clinicians to 
reduce the number of admissions and its duration. It has been 
proposed that clinicians may use APP to obtain quicker clinical 
responses in either inpatient26 or outpatient settings.16 Further‑
more, APP may be continued in the outpatient setting, instead 
of changed to monotherapy, to avoid relapses.16 The shortage 
of resources in psychosocial support and community ‑based 
rehabilitation programs for people with serious mental illness 
may also contribute to the observed prescription pattern. 
Last but not the least, psychiatric resources are asymmetrical‑
ly distributed in Portugal, with the countryside facing greater 
challenges than the metropolitan areas.27 The literature also 
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reports that rural settings are more associated with long ‑term 
APP, which may have also had contributed to our APP rate.21
APP is not recommended unless other trials in monotherapy, 
including clozapine, fail to demonstrate efficacy. In our sam‑
ple, there was a clear discrepancy between the number of pa‑
tients with schizophrenia and other psychosis and the number 
of patients prescribed with clozapine. It may be possible that, 
if more patients were prescribed with clozapine, there would 
be a lower rate of APP; however, our population contained, 
by definition, patients on LAIA, which means that patients on 
clozapine and LAIA would necessarily qualify as APP. 
We observed a rate of 14.4% of APHD in the study sample, 
similar to other studies in Portuguese populations.8 Higher 
rates were found on populations receiving compulsory 
treatment, as shown in an Australian study,24 which found 
27% of APHD, and a Portuguese one,18 which obtained a 
rate of 51.4%. On the other hand, inpatient and community 
studies on UK,26 Scotland28 and Hong ‑Kong29 found lower 
rates of APHD, 10%, 2% and 9.2%, respectively.
APHD showed a significant statistical association with pre‑
vious hospitalization and prescription of anticholinergics. 
No significant statistical association has been found between 
APHD and sex or age. Additionally, no significant statistical 
difference has been found between different marital status and 
different clinical diagnosis (ICD ‑10) with regard to APHD.
The association between APHD and the use of anticholin‑
ergics was also found in past studies.18 APHD was associ‑
ated with APP, as reported in other studies.8,24,26 It has been 
hypothesized that it becomes increasingly difficult for cli‑
nicians to calculate total AP dosages in patients prescribed 
with more than one AP.8 
a. Strengths and limitations
To the best of our knowledge, this is the first study report‑
ing on APP and APHD prescription patterns in patients on 
a community mental health service in Portugal. 
However, it presents several limitations. Firstly, its retro‑
spective design may have compromised the quality of the 
data and introduced errors, as we could only acquire data 
present in clinical records. Secondly, as a cross ‑sectional 
study, we did not possess data on evolution of AP prescrip‑
tion, so we remained blind to possible ongoing AP cross‑
‑titration switches or short ‑term oral AP prescriptions. We 
were also unaware of the previous AP trials of each pa‑
tient, so we are unable to address whether APP was a last 
resource following multiple monotherapy trials, including 
clozapine. Lastly, we report specifically on patients on a 
rural community mental health service receiving LAIA, 
so our results may not be generalized to other settings 
and populations. However, our specificity fills a gap on 
the literature, particularly when it comes to Portuguese 
populations. 
CONCLUSION
The present study reveals the prescription patterns on a ru‑
ral Portuguese community mental health service user pop‑
ulation. High prevalences of APP and APHD have been 
identified, as well as some sociodemographic and clinic 
factors that are statistically meaningful to the observed 
patterns. Given the scarcity of studies about APP an APHD 
in Portugal, further studies are required to better evaluate 
and optimize the antipsychotic prescription pattern, in or‑
der to meet international guidelines and standards.
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